Sweet 1985

Methods	Randomized controlled trial.
Participants	Inclusion criteria: none stated. Exclusion criteria: none stated. Number of women randomized: 60; 30 in each group. Number of women analyzed: 60; 30 in each group. Number of withdrawals/exclusions/loss to follow‐up and reasons: 0 reported as lost to follow‐up. Number of centres: 1. Age (mean ± SD) (years): group A: 24.2 ± 5.1; group B: 24.7 ± 7.2. Country: US.
Interventions	Group A: moxalactam 2 g IV every 8 h. Group B: clindamycin 600 mg IV every 6 h + tobramycin 1.5 mg/kg every 8 h.
Outcomes	Primary outcome: microbiological cure. Secondary outcome: length of hospital stay.
Notes	Ethical approval: not stated. Informed consent: yes, all women gave informed consent approved by the University of California (San Francisco) Committee on Human Research. Source of funding: not stated, and no conflicts of interest reported.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Women randomized using a computer‐generated randomized schedule.
Allocation concealment (selection bias)	Unclear risk	Not stated.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not stated.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated.
Incomplete outcome data (attrition bias) All outcomes	Low risk	All women randomized were analyzed.
Selective reporting (reporting bias)	Unclear risk	No study protocol found.
Other bias	Unclear risk	Not stated.